Vitamin D Levels Predict Multiple Sclerosis Progression

NIH | APRIL 27, 2014

Among people with early-stage multiple sclerosis (MS), those with higher blood levels of vitamin D had better outcomes during 5 years of follow-up. Identifying and correcting vitamin D insufficiency could aid in the early treatment of MS.

MS is an unpredictable disease of the central nervous system that disrupts communication between the brain and other parts of the body. It’s believed to be an autoimmune disease, in which the immune system mistakenly attacks the myelin sheaths that insulate nerves. The disease can range from relatively mild to devastating.

People who have low levels of vitamin D intake or low blood levels of vitamin D have a higher risk for MS. This suggests that vitamin D is related to the disease, but it’s unclear whether low vitamin D levels are a cause or a consequence of MS.

An international team of researchers, led by Dr. Alberto Ascherio of Harvard School of Public Health, set out to assess whether vitamin D status early in the disease process influences the long-term course of the disease.

The team examined data from 465 people with early-stage MS who were enrolled in a large clinical trial originally designed to evaluate an MS drug called interferon beta-1b. The participants—from 18 European countries, Israel, and Canada—were mostly white individuals of European ancestry.

A common marker of vitamin D status—serum concentrations of 25-hydroxyvitamin D (25[OH]D)—was measured at baseline (the onset of symptoms) and 6, 12, and 24 months later.

Participants were followed for 5 years with clinical assessments and MRI scans to monitor brain lesions and brain volume. Data were adjusted for age, sex, body mass index, and seasonal variation in vitamin D levels.

The researchers found that higher serum 25(OH)D levels in the first 12 months predicted reduced MS activity and a slower rate of MS progression. By the end of the follow-up at 5 years, participants with serum 25(OH)D concentrations of at least 50 nmol/L (20-ng/mL, a moderate level) had significantly fewer new active lesions, a slower increase in brain lesion volume, lower loss of brain volume, and lower disability than those with serum 25(OH)D concentrations below 50 nmol/L.

These results suggest that vitamin D has a protective effect on the disease process underlying MS.

YOU MAY ALSO LIKE

Rare cancers may masquerade as ADHD in children

Rare tumors called pheochromocytomas and paragangliomas may cause the same symptoms as attention deficit hyperactivity disorder (ADHD) in children, leading to inappropriate treatment that could worsen their symptoms and potentially endanger their health.

Scientists design a new hydrogel that helps regenerate cartilage

An international team of scientists demonstrates that polyacrylate hydrogels create the support and microenvironment necessary for the growth and maintenance of cartilage cells (chondrocytes), and could be optimal candidates for use in clinical practice.

Biomarker Signatures of Prostate Cancer

A recent study revealed biomarker combinations in urine that are unique to prostate cancer and 2 of its stages. The findings suggest a noninvasive approach to diagnosing prostate cancer and assessing tumor progression.

New findings reveal how microbiome is disrupted during disease flare-ups

A study led by researchers from the Harvard T.H. Chan School of Public Health and the Broad Institute of MIT and Harvard is the first to observe the complex set of biochemical and molecular events that disrupt the microbiome and trigger immune responses during flare-ups of inflammatory bowel diseases.

Artificial Sweeteners Can Still Lead to Obesity, Diabetes

Maybe switching from regular soda to diet doesn’t help as much as we thought.

Fecal microbiota transplantation helps restore beneficial bacteria in cancer patients

Researchers at Memorial Sloan Kettering Cancer Center have shown that autologous fecal microbiota transplantation (auto-FMT) is a safe and effective way to help replenish beneficial gut bacteria in cancer patients who require intense antibiotics during allogenic hematopoietic stem cell transplantation.